Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2551 to 2600 of 3761 results for treatment

  1. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for vaginal vault prolapse

    prolapse can cause discomfort and problems with urination. There are some treatment options that don't involve surgery that NICE says...

  2. Evidence summaries: new medicines – Integrated process statement (PMG11)

    This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs

  3. The RhinoChill intranasal cooling system for reducing temperature after cardiac arrest (MIB4)

    NICE has developed a Medtech Innovation Briefing (MIB) on the RhinoChill intranasal cooling system

    Medtech innovation briefing
    Published
    1 February 2014

  4. Artificial intelligence (AI) and digital regulations service

    We're playing a leading role in the AI and digital regulations service which supports the development and adoption of AI and data-driven technologies in health and care.

  5. How we support healthtech commissioning

    therapy for children with anxiety or low mood Providing an additional treatment pathway, this tech is recommended for early use while...

  6. Thermogard XP for therapeutic hypothermia after cardiac arrest (MIB37)

    NICE has developed a medtech innovation briefing (MIB) on Thermogard XP for therapeutic hypothermia after cardiac arrest

    Medtech innovation briefing
    Published
    9 September 2015

  7. ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB61)

    NICE has developed a medtech innovation briefing (MIB) on the ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation

    Medtech innovation briefing
    Published
    23 March 2016

  8. Laparoscopic mobilisation of the greater omentum for breast reconstruction (HTG162)

    Evidence-based recommendations on laparoscopic mobilisation of the greater omentum for breast reconstruction. This involves removing the fatty tissue using special instruments through small cuts in the abdomen.

    HealthTech guidance
    Published
    27 February 2008
    View recommendations

    Sections for HTG162

  9. Laparoscopic prostatectomy for benign prostatic obstruction (HTG176)

    Evidence-based recommendations on laparoscopic prostatectomy for benign prostatic obstruction. This involves removing the prostate through small cuts in the abdomen, using a fine telescope to see inside the body (keyhole surgery).

    HealthTech guidance
    Published
    26 November 2008
    View recommendations

    Sections for HTG176

  10. Diabetes in pregnancy (QS109)

    This quality standard covers managing diabetes and its complications in women who are planning a pregnancy or are already pregnant. It includes care for women with pre-existing diabetes before and during pregnancy, and diagnosis and management of gestational diabetes. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    10 January 2023
    View quality statements

    Sections for QS109

  11. Transient loss of consciousness ('blackouts') in over 16s (QS71)

    This quality standard covers assessing, diagnosing and referring people (aged 16 and over) who have had a transient loss of consciousness (often called a blackout). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    2 October 2014
    View quality statements

    Sections for QS71

  12. Percutaneous vertebroplasty (HTG3)

    Evidence-based recommendations on percutaneous vertebroplasty for spinal metastases. This involves injecting a special bone cement into the spine to relieve pain and stabilise the fracture site.

    HealthTech guidance
    Published
    24 September 2003
    View recommendations

    Sections for HTG3

  13. ColonFlag for identifying people at risk of colorectal cancer (MIB142)

    NICE has developed a medtech innovation briefing (MIB) on ColonFlag for identifying people at risk of colorectal cancer .

    Medtech innovation briefing
    Published
    12 April 2018

  14. Familial breast cancer. Patient decision aid on taking a medicine to reduce the chance of developing breast cancer for postmenopausal women at moderately increased risk

    lower baseline risk than this, and what this means about the effects of treatment. Remember that no-one can say what will happen to any...

  15. Fetal monitoring in labour (NG229)

    This guideline covers methods for monitoring the wellbeing of the baby during labour. It includes risk assessment to determine the appropriate level of fetal monitoring, using clinical assessment in addition to fetal monitoring, and interpreting and acting on monitoring findings.

    NICE guideline
    Last updated
    12 November 2025
    View recommendations

    Sections for NG229

  16. GreenLight XPS for treating benign prostatic hyperplasia (HTG650)

    Evidence-based recommendations on GreenLight XPS for treating benign prostatic hyperplasia.

    HealthTech guidance
    Published
    29 November 2022
    View recommendations

    Sections for HTG650

  17. Woundchek Protease Status for assessing elevated protease status in chronic wounds (MIB83)

    NICE has developed a medtech innovation briefing (MIB) on the Woundchek Protease Status for assessing elevated protease status in chronic wounds .

    Medtech innovation briefing
    Published
    5 October 2016

  18. Types of recommendation NICE can make

    NICE makes 4 types of recommendation that allow us to produce clear, directive, actionable guidance that is easy to understand and put into practice.

  19. Percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices (HTG251)

    Evidence-based recommendations on percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices. This involves using a special cutting device to remove excess debris inside diseased blood vessels.

    HealthTech guidance
    Published
    23 February 2011
    View recommendations

    Sections for HTG251

  20. Therapeutic hypothermia with intracorporeal temperature monitoring for hypoxic perinatal brain injury (HTG221)

    Evidence-based recommendations on therapeutic hypothermia with intracorporeal temperature monitoring for hypoxic perinatal brain injury. This involves cooling either the baby's head or whole body to prevent brain damage.

    HealthTech guidance
    Published
    26 May 2010
    View recommendations

    Sections for HTG221

  21. Peptest for diagnosing gastro‑oesophageal reflux (MIB31)

    NICE has developed a medtech innovation briefing (MIB) on Peptest for diagnosing gastro-oesophageal reflux

    Medtech innovation briefing
    Published
    22 May 2015

  22. Safe midwifery staffing for maternity settings (NG4)

    This guideline covers safe midwifery staffing in all maternity settings, including at home, in the community, in day assessment units, in obstetric units, and in units led by midwives (both alongside hospitals and free-standing). It aims to improve maternity care by giving advice on monitoring staffing levels and actions to take if there are not enough midwives to meet the needs of women and babies in the service.

    NICE guideline
    Published
    27 February 2015
    View recommendations

    Sections for NG4

  23. Percutaneous endoscopic laser thoracic discectomy (HTG34)

    Evidence-based recommendations on percutaneous endoscopic laser thoracic discectomy. This involves using a laser to heat and destroy some of the inside of the disc and shrink the part that is sticking out.

    HealthTech guidance
    Published
    27 May 2004
    View recommendations

    Sections for HTG34

  24. Balloon dilatation with or without stenting for pulmonary artery or non-valvar right ventricular outflow tract obstruction in children (HTG47)

    Evidence-based recommendations on balloon dilatation with or without stenting for pulmonary artery or non-valvar right ventricular outflow tract obstruction in children. This involves using a balloon to widen the narrow area of the heart to let blood flow through it more easily.

    HealthTech guidance
    Published
    28 July 2004
    View recommendations

    Sections for HTG47

  25. PLASMA system with button electrode for electrovaporisation of the prostate (MIB274)

    NICE has developed a medtech innovation briefing (MIB) on PLASMA system with button electrode for electrovaporisation of the prostate .

    Medtech innovation briefing
    Published
    31 August 2021

  26. VA ECMO for postcardiotomy cardiogenic shock in adults (HTG762)

    Evidence-based recommendations on venoarterial extracorporeal membrane oxygenation (VA ECMO) for postcardiotomy cardiogenic shock in adults. This involves using an artificial lung to oxygenate the blood outside the body.

    HealthTech guidance
    Published
    18 December 2025

    Sections for HTG762

  27. Cryotherapy for the treatment of liver metastases (IPG369)

    Interventional procedures, IPG369 - Issued: December 2010 --> We have moved interventional procedures guidance 369 to become HealthTech guidance 241. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  28. Abatacept for the treatment of rheumatoid arthritis (TA141)

    This appraisal has been updated and replaced by NICE technology appraisal guidance 195.

    Withdrawn guidance

  29. Adalimumab for the treatment of psoriatic arthritis (TA125)

    This guidance has been updated and replaced by NICE technology appraisal guidance 199.

    Withdrawn guidance

  30. Rituximab for the treatment of rheumatoid arthritis (TA126)

    This guidance has been updated and replaced by NICE technology appraisal guidance 195.

    Withdrawn guidance

  31. Golimumab for the treatment of ankylosing spondylitis (TA233)

    This guidance has been updated and replaced by NICE technology appraisal guidance 383.

    Withdrawn guidance

  32. Tocilizumab for the treatment of rheumatoid arthritis (TA198)

    This guidance has been updated and replaced by NICE technology appraisal guidance 247.

    Withdrawn guidance

  33. Rituximab for the treatment of follicular lymphoma (TA110)

    This guidance has been updated and replaced by NICE technology appraisal guidance 243.

    Withdrawn guidance

  34. Taxanes for the treatment of breast cancer (TA6)

    This guidance has been replaced by NICE technology appraisal guidance 30 [Replaced by NICE guideline CG81].

    Withdrawn guidance

  35. Taxanes for the treatment of breast cancer (TA30)

    This guidance has been replaced by NICE guideline CG81.

    Withdrawn guidance

  36. High-risk groups:- What interventions to prevent infection and reduce antimicrobial resistance are effective for groups of people at high risk of infection? This includes people who:- have suppressed immune systems (for example, because of HIV, an inherited condition or treatment they may be having for conditions such as cancer or an organ transplant)- have a chronic disease- live in crowded conditions (see Shelter's definition)- are homeless- have been in prison- have migrated from countries with a high prevalence of infectious diseases such as tuberculosis (examples include South Asia and sub-Saharan Africa).

    immune systems (for example, because of HIV, an inherited condition or treatment they may be having for conditions such as cancer or an...

    Research recommendation
    Published
    17 February 2017

  37. Flu treatment - zanamivir, amantadine and oseltamivir (TA58)

    This guidance has been updated and replaced by NICE technology appraisal guidance 168.

    Withdrawn guidance

  38. Elranatamab for treating relapsed or refractory multiple myeloma after treatments including anti-CD38 antibody and lenalidomide therapy [ID6591]

    Awaiting development Reference number: GID-TA11753 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  39. Type 2 diabetes in adults. Patient decision aid on type 2 diabetes: agreeing my blood glucose (HbA1c) target

    2 diabetes find their HbA1c increases over time, even with treatment. That's why treatments may need to be changed as part...

  40. Hand allotransplantation (HTG254)

    Evidence-based recommendations on hand transplant surgery (allotransplantation). This involves transplanting a hand from a recently deceased donor onto the amputated stump.

    HealthTech guidance
    Published
    23 March 2011
    View recommendations

    Sections for HTG254

  41. Laser-assisted cerebral vascular anastomosis without temporary arterial occlusion (HTG161)

    Evidence-based recommendations on laser-assisted cerebral vascular anastomosis without temporary arterial occlusion. This involves using a special laser device to create a bypass without the need to temporarily interrupt the blood flow to the brain.

    HealthTech guidance
    Published
    27 February 2008
    View recommendations

    Sections for HTG161

  42. Transcatheter endovascular closure of perimembranous ventricular septal defect (HTG213)

    Evidence-based recommendations on transcatheter endovascular closure of perimembranous ventricular septal defect. This involves inserting a small blocking device (called an occluder) into the heart.

    HealthTech guidance
    Published
    24 March 2010
    View recommendations

    Sections for HTG213

  43. Endoscopic mastectomy and endoscopic wide local excision for breast cancer (HTG188)

    Evidence-based recommendations on endoscopic mastectomy and endoscopic wide local excision for breast cancer. This involves removing part or all of the breast using special instruments inserted through small cuts in the skin (keyhole surgery).

    HealthTech guidance
    Published
    22 April 2009
    View recommendations

    Sections for HTG188

  44. Tests in secondary care to identify people at high risk of ovarian cancer (HTG453)

    Evidence-based recommendations on tests in secondary care to identify people at high risk of ovarian cancer. The tests are the IOTA ADNEX model, Overa (MIA2G), RMI I (at thresholds other than 250), ROMA and IOTA Simple Rules.

    HealthTech guidance
    Published
    15 November 2017
    View recommendations

    Sections for HTG453

  45. Molecular testing strategies for Lynch syndrome in people with colorectal cancer (HTG430)

    Evidence-based recommendations on using immunohistochemistry or microsatellite instability testing to guide further testing for Lynch syndrome in people with colorectal cancer.

    HealthTech guidance
    Published
    22 February 2017
    View recommendations

    Sections for HTG430

  46. Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: late-stage assessment (HTG757)

    Late stage assessment (LSA) guidance on transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis.

    HealthTech guidance
    Published
    21 August 2025
    View recommendations

    Sections for HTG757

  47. New pharmaceutical treatments for non-Alzheimer dementias [ID380]

    Discontinued Reference number: GID-TAG369

    Technology appraisal guidance
    Discontinued

  48. Further research is recommended to resolve uncertainties about the cost effectiveness of fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema. This should focus on a group of patients whose condition is unresponsive to other available therapies, and include measures of efficacy and health-related quality of life. Research should focus on identifying appropriate utility values, taking into account the utility values for different levels of visual acuity and the relative relationship in utility values from treating the best-seeing and the worse-seeing eye. The appropriateness of generalising utility values from one group of eye conditions to another group would also be of value.

    cost effectiveness of fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema. This should...

    Research recommendation
    Published
    9 June 2015

  49. CytoSorb for reducing risk of bleeding during cardiac surgery (MIB249)

    NICE has developed a medtech innovation briefing (MIB) on CytoSorb for reducing risk of bleeding during cardiac surgery .

    Medtech innovation briefing
    Published
    2 February 2021

  50. Zanamivir for the treatment of influenza in adults (TA15)

    This guidance has been replaced by NICE technology appraisal guidance 58 [Replaced by NICE technology appraisal guidance 168].

    Withdrawn guidance